Результаты поиска

Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients.

Graft versus host disease (GVHD) remains one of the leading causes of morbidity and mortality associated with conventional allogeneic hematopoietic stem cell transplantation (HCT). The use of T-cell depletion significantly reduces this complication. Recent prospective and retrospective data suggest that, in patients with AML in first complete remission, CD34+ selected grafts afford overall and relapse-free survival comparable to those observed in recipients of conventional grafts, while significantly decreasing GVHD. In addition, CD34+ selected grafts allow older patients, and those with medic

Совпадение в полном тексте источника
… The addition of antithymocyte globulin (ATG) and thiotepa to the conditioning regimens, which had traditionally included cyclophosphamide and total body irradiation (TBI) or busulfan, decreased the rate of graft failure and eliminated the need for post transplant GVHD prophylaxis. … The study included 44 patients with AML in CR1 or CR2 (excluding patients with t (15;17), and core binding factor leukemia) who received T cell depleted PBSCT from HLA-identical siblings after conditioning with hyperfractionated TBI (HFTBI), thiotepa, cyclophosphamide and ATG. …

Implications of acute coronavirus disease 2019 during haematopoietic stem cell transplantation-Experience from real-world clinical practice.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… ALC, absolute lymphocyte count; ANC, absolute neutrophil count; Bu, busulphan; COVID‐19, coronavirus disease 2019; Flu, fludarabine; ICU, intensive care unit; Mel, melphalan; PTCy, post‐transplant cyclophosphamide; TT, thiotepa; VNTR, variable nucleotide tandem repeat. …

Prevention of veno-occlusive disease/sinusoidal obstruction syndrome: a never-ending story and no easy answer.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Shadur et al. [ 11 ] reported no VOD/SOS on 31 IMO patients using a treosulfan, fludarabine and thiotepa-based MAC regimen with an overall survival of 100%. …

A prognostic index for multiple myeloma.

The current prognostic systems have failed to identify multiple myeloma (MM) patients who require aggressive therapy. These staging systems do not reliably distinguish patients with different prognoses. This paper explores the possibility of improving the prognostic forecast in MM by considering some clinical characteristics at diagnosis together with response to first-line chemotherapy. A total of 231 patients were prospectively randomised in a multicentre trial to no therapy vs melphalan + prednisone (MP) for stage I, MP in stage II, and MP vs peptichemio, vincristine and prednisone for stag

Совпадение в полном тексте источника
… Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. 82 8 15 10 1993 2324 2328 Blood 8104539 Drewinko B. Alexanian R. Boyer H. Barlogie B. Rubinow S. I. …

Hematopoietic stem cell transplantation: an Italian monocentric experience on the health assessment and eligibility of adult-related donors.

IntroductionIndications for HSCT are increasing worldwide, paralleled by a growing demand for donors of therapeutic cells.MethodsHerein, we report our real-world experience of adult HPC donor assessment during a 5-year study period (2018-2023): we have retrospectively revised data of 455 potential related stem cell donors, consecutively evaluated at our center. Donor medical history was assessed by a questionnaire and an interview with a trained physician experienced in donation procedures to evaluate donor fitness and medical history. Pre-existing health disorders were fully investigated. Beh

Совпадение в полном тексте источника
… In particular, MAC regimens consisted of fludarabine and total body irradiation (FLU-TBI; fludarabine 120 mg/m 2 , followed by 9–12 Gy TBI) or thiotepa, busulfan, fludarabine (TBF; thiotepa 5 mg/kg on day −6 and −5 total; intravenous busulfan 3.2 mg/kg on day −4, −3, and −2; fludarabine 50 mg/m 2 on …

Cardiopulmonary performance in allogeneic hematopoietic cell transplantation recipients-evaluation of pre-transplant risk assessments.

Cardiopulmonary performance reflects how well different organ systems interact. It is inter alia influenced by body composition, determines patients' quality of life and can also predict mortality. However, it is not yet used for risk prediction prior to allogeneic hematopoietic cell transplantations (alloHCT). Thus, we aimed to examine the predictive power of peak oxygen consumption (VO2peak) as a representative of cardiopulmonary performance and that of body composition before alloHCT to determine overall survival (OS) and non-relapse mortality (NRM) 2 years after transplantation. We also co

Совпадение в полном тексте источника
… 25.6) 0 Missing data e 8 (13.6) 0 8 (50) Causes of death [ n ] b Alive 43 (72.9) 43 (100) 0 Relapse/progression disease 4 (6.8) 0 4 (25) Organ failure 1 (1.7 0 1 (6.3) GVHD 5 (8.5) 0 5 (31.3) Infection 6 (10.2) 0 6 (37.5) 2yrsS 2-year survivor, 2yrsD 2-year decedents, HLA human leukocyte antigen, TT thiotepa … Table 2 Patient characteristics. 2yrsS 2-year survivor, 2yrsD 2-year decedents, HLA human leukocyte antigen, TT thiotepa, BU busulfan, FLU fludarabine, TBI total body irradiation, VP16 etoposide, BCNU camustin, MEL melphalan, TREOS treosulfan, ALL acute lymphocytic leukemia, CR complete remission, KPS …

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma.

BackgroundHigh-dose melphalan (200 mg/m(2)) with autologous stem cell transplantation (ASCT) is the standard treatment for young patients with multiple myeloma (MM). However, the response rates after ASCT are often unsatisfactory. We performed a pilot study by using bortezomib-melphalan as conditioning regimen for ASCT in Korean patients with MM.MethodsThe conditioning regimen consisted of administration of intravenous infusion of bortezomib 1.0 mg/m(2) on days -4 and -1 and melphalan 50 mg/m(2) (day -4) and 150 mg/m(2) (day -1). In this study, we enrolled 6 newly diagnosed patients and 2 pati

Совпадение в полном тексте источника
… Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004;100:2607–2612. doi: 10.1002/cncr.20294. 7. Richardson PG, Barlogie B, Berenson J, et al. …

Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT).

SOS/VOD is a life-threatening complication of hematopoietic stem cell transplantation, especially in children, with incidences reaching up to 15-20%. Despite efforts, SOS/VOD remains unpredictable with significant morbidity and mortality. High-risk criteria are clearly defined, and the pediatric EBMT diagnostic criteria have improved sensitivity, reducing treatment delays and enhancing outcomes. A meta-analysis combining retrospective and prospective studies found a risk ratio of 0.30 for SOS/VOD with defibrotide (DF) prophylaxis. Additionally, two prospective trials were conducted: the pediat

Совпадение в полном тексте источника
… Shadur et al. [ 41 ] reported on thirty-one patients with MIOP who underwent HSCT with a fludarabine/treosulfan/thiotepa (FTT)-based regimen, noting no SOS/VOD and an OS of 100%. … Partly because treosulfan is regarded as myeloablative only when combined with thiotepa [ 73 ], which, as a second alkylator, can pose a risk of VOD/SOS. …

Particularities of Neurological Manifestations in Adult T-Cell Leukemia/Lymphoma: Need for a Multidisciplinary Approach-A Narrative Review.

ATL is a rare but a highly aggressive T-cell neoplasm associated with human T-cell leukemia virus-1 (HTLV-1) infection. Human T-cell lymphotropic virus type-1 (HTLV-1) is a oncogenic retrovirus responsible for the development of adult T-cell leukemia (ATL), but also for other non-malignant diseases, such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-1 has a higher prevalence in Japan, the Caribbean, South America, intertropical Africa, Romania, and northern Iran. ATL patients can have an extensive spectrum of neurological manifestations. Numerous factors can be i

Совпадение в полном тексте источника
… According to current recommendations, a conditioning regimen which includes drugs that can cross the blood-brain barrier, such as Thiotepa should be considered [ 9 ]. Additionally, CNS disease patients may benefit from graft-versus-leukemia effect. … Intensive chemotherapy with drugs that can cross the blood–brain barrier, such as methotrexate, thiotepa, and cytarabine, is widely applied [ 62 , 63 ]. However, the clinical outcome is typically poor [ 63 ]. 4. HAM/TSP 4.1. …

The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session (O010-O173).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Comparable Outcomes of AML Patients Receiving Haplo-HCT with Thiotepa/Busulfan/Fludarabine Conditioning and Post-Transplant Cyclophosphamide Versus a Matched Unrelated Donor with Fludarabine/Busulfan Conditioning, Regardless of Disease Status Ali Bazarbachi 1 , Myriam Labopin 2 , Didier Blaise 3 , Edouard … All patients received thiotepa at Σ10mg/kg, fludarabine at Σ150mg/kg and bortezomib at 1.3mg/m 2 on days -5,-2,+2,+5. Anti-thymocyte globulin serotherapy was abandoned. Tocilizumab at 8 mg/kg at day 0 and abatacept at 10 mg/kg at days 0,7,14 and 28 were administered instead. …

Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion.

COVID-19 caused by SARS-Cov-2 is a devastating infection in patients with hematological malignancies. In 2018, the Lebanese Society of Hematology and Blood Transfusion (LSHBT) updated the guidelines for the management of hematological malignancies in Lebanon. In 2019, it was followed by a second update. Given the rapidly changing evidence and general situation for COVID-19, the LSHBT established some recommendations and suggestions for the management of the patients with hematological malignancies taking into account the Lebanese condition, economic situation, and the facts that SARS-Cov-2 inf

Совпадение в полном тексте источника
… Thiotepa should be omitted for elderly patients ( 38 ). For autologous transplant as consolidation therapy, reduction of the doses of thiotepa should be done. …

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Sessions

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Four pts underwent allogeneic peripheral stem cell transplantation from an identical donor with a conditioning associating total body irradiation and Cyclophosmamide in 2 and TBF (Thiotepa, Bisulfex, Fludarabine) in 2 other pts. …

Изучение последствий трансплантации гематопоиетических клеток: 18- годовое исследование посттрансплантационных новообразований.

ВВЕДЕНИЕ: Улучшается трансплантация стволовых клеток после гематотипии (ХХТ) с увеличением числа выживших жертв. Особую озабоченность вызывают последующие новообразования (СН) в связи с ПЗТ. МЕТОДЫ: С января 2003 и декабрь 2022, учетные записи получателей ВСТ были ретроспективно проанализированы. Результаты: на медианной основе 108 месяцев (дальность, 0.13-215), 2659 Пациенты получали ТХТ. Из них 1131 (В тыс.43%) были <18 ..старше. Аллогенетические ЦХТ были проведены в 1476 (В тыс.56%) пациентов. Myeloablatory (MAC) была использована в 2157 (В тыс.81%) и 583(В тыс.22%) получил TBI. При медиане

Совпадение в полном тексте источника
… acute lymphoblastic leukemia; PTLD, Post-Transplant Lymphoproliferative Disorder; RAEB, refractory anemia with excess blasts; RCC, renal cell carcinoma; RIC, reduced-intensity conditioning; SCC, squamous-cell carcinoma; T-ALL, T-cell acute lymphoblastic leukemia; TBI, total body irradiation; TEAM, thiotepa … , etoposide, cytarabine, melphalan; TT, thiotepa; UCB, unrelated cord blood. …

Donor's age influences outcome in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide - a single center experience.

Haploidentical stem cell transplantation (haplo-SCT) using post-transplantation cyclophosphamide (post-Cy) is considered a reasonable therapeutic option for patients who lack matched donor or who urgently need transplant procedure due to high risk disease. We analyzed the results of haplo-SCT performed in years 2018-2023. Eighty one patients (46 males) at median age of 52 years underwent haplo-SCT using peripheral blood as a stem cell source in most cases. Indications included hematological malignancies (acute leukemias in 88% of cases). In 25 cases (31%) transplantation was performed in relap

Совпадение в полном тексте источника
… neutrophil engraftment, median, IQR Days to platelet engraftment, median, IQR 21 (19–23) 19 (14–24) Day 30 donor chimerism in %, median, IQR 99.25 (98.5–100) BU : busulfan; CMV : cytomegalovirus; CY : cyclophosphamide; FLU : fludarabine; IQR : interquartile range; TBI : total body irradiation; TT : thiotepa … Table 2 Transplant data BU : busulfan; CMV : cytomegalovirus; CY : cyclophosphamide; FLU : fludarabine; IQR : interquartile range; TBI : total body irradiation; TT : thiotepa Patients, n , % | 81 (100%) Donor age in years, median, IQR | 38 (32–44) Female donor to male recipient, n, % | 16 (20) CMV …

Case report: Relapsed/refractory extranodal natural killer/T-cell lymphoma nasal type with extensive central nervous system involvement.

Background: Extranodal natural killer/T-cell lymphoma (ENKL) is a rare subtype of mature T and natural killer cell lymphomas associated with Epstein-Barr virus. Case: A 20-year-old presented with severe neurological symptoms and was diagnosed with stage IV ENKL, nasal type, with CNS involvement. Overall, the patient received nine treatment lines, including chemotherapy, craniospinal irradiation, allogeneic stem cell transplant (alloSCT), donor lymphocyte infusions, and novel agents (Nivolumab, Daratumumab, Thalidomide, Lenalidomide, virus-specific T cells) combined with intrathecal chemotherap

Совпадение в полном тексте источника
… It is debatable whether the myeloablative conditioning with CNS penetrating agents Busulphan and Thiotepa would have eradicated the residual CNS disease, but the patient’s condition was unsuitable for a more intensive conditioning regimen at that moment. …

Iron deprivation in cancer--potential therapeutic implications.

Iron is essential for normal cellular function. It participates in a wide variety of cellular processes, including cellular respiration, DNA synthesis, and macromolecule biosynthesis. Iron is required for cell growth and proliferation, and changes in intracellular iron availability can have significant effects on cell cycle regulation, cellular metabolism, and cell division. Perhaps not surprisingly then, neoplastic cells have been found to have higher iron requirements than normal, non-malignant cells. Iron depletion through chelation has been explored as a possible therapeutic intervention i

Совпадение в полном тексте источника
… The European D-CECaT trial, which used DFO in combination with cyclophosphamide, etoposide, carboplatin, and thiotepa showed some promising preliminary results. This was a single arm trial for advanced stage neuroblastoma, and included 57 evaluable patients. … Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: Preliminary results. Italian neuroblastoma cooperative group. Eur. J. Cancer. 1995;31A:612–615. doi: 10.1016/0959-8049(95)00068-t. 113. …

GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation.

We present the largest prospective real-world experience in 159 patients who received the triple combination of tacrolimus/sirolimus/mycophenolate mofetil after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-alloHSCT) from matched-related (MRD), matched-unrelated (MUD) or mismatched-unrelated donors (MMURD). Despite the high-risk and elderly population, non-relapse mortality (NRM) at day +100 and 1 year was 5.1% and 8.6%. Grades 2-4 and 3-4 acute Graft-versus-host disease (GvHD) at day +180 was 30.3% and 13%, respectively. Chronic GvHD at 1 and 3 years w

Совпадение в полном тексте источника
… RIC regimens were mainly based on thiotepa, fludarabine, and busulfan (TBF-RIC) or busulfan and fludarabine (Bu-Flu-RIC): fludarabine (150 mg/m 2 ) and busulfan (8 mg/kg) with or without thiotepa (10 mg/kg). Patients were nursed in HEPA-filtered rooms. …

Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France.

The real-world clinical and economic burden of graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation has not been comprehensively studied in France. Clinical outcomes, healthcare resource utilization and costs associated with acute GVHD (aGVHD), chronic GVHD (cGVHD), acute plus chronic GVHD (a+cGVHD) versus no GVHD were compared using French administrative claims data. After propensity score matching, 1934, 408, and 1268 matched pairs were retained for the aGVHD, cGVHD, and a+cGVHD cohorts, respectively. Compared with patients with no GVHD, odds of devel

Совпадение в полном тексте источника
… Cyclophosphamide, melphalan, carmustine, thiotepa, antithymocyte immunoglobulin, treosulfan, fludarabine, and etoposide were also looked at but were not presented as n < 5 for each, and the std diff was 0 across all groups. e GVHD prophylaxis was administrated before the first documented GVHD and after … Cyclophosphamide, melphalan, carmustine, thiotepa, antithymocyte immunoglobulin, treosulfan, fludarabine, and etoposide were also looked at but were not presented as n < 5 for each, and the std diff was 0 across all groups. e GVHD prophylaxis was administrated before the first documented GVHD and after …

Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice.

The impressive advances in the knowledge of biomarkers and molecular targets has enabled significant progress in drug therapy for crucial diseases such as cancer. Specific areas of pharmacology have contributed to these therapeutic outcomes-mainly targeted therapy, immunomodulatory therapy, and gene therapy. This review focuses on the pharmacological profiles of these therapeutic classes and intends, on the one hand, to provide a systematic definition and, on the other, to highlight some aspects related to pharmacovigilance, namely the monitoring of safety and the identification of potential t

Совпадение в полном тексте источника
… | 2 | •Acute lymphoblastic leukemia (ALL) •Acute myeloid leukemia (AML) •Myelodysplastic syndromes (MDS) •NK-cell leukemia •Hodgkin lymphoma •non-Hodgkin lymphoma (NHL) •Juvenile myelomonocytic leukemia (JMML) •Chronic myeloid leukemia (CML) | •Drug: Cyclophosphamide •Biological: Fludarabine •Drug: Thiotepa … leukemia (CML) •Juvenile myelomonocytic leukemia (JMML) •Myelodysplastic syndrome (MDS) •Non-Hodgkin lymphoma (NHL) | •Drug: Anti-thymocyte globulin (rabbit) •Drug: Blinatumomab •Drug: Cyclophosphamide •Drug: Fludarabine •Drug: G-CSF •Drug: Melphalan •Drug: Mesna •Drug: Rituximab•Drug: Tacrolimus •Drug: Thiotepa …

15th Report on Carcinogens.

BACKGROUND: The Report on Carcinogens (RoC) is a congressionally mandated, science-based public health document that the National Toxicology … in; Tetrachloroethylene; Tetrafluoroethylene; Tetranitromethane; Thioacetamide; 4,4'-Thiodianiline; Thiotepa; Thiourea; Thorium Dioxide (see Ionizing Radiation); Tobacco Smoke, Environmental (see Tobacco-Related Exposures); Tobacco, Smokeless (see Tobacco-Related Exposures); Tobacco Smoking (see Tobacco-Related Exposures); Toluene Diisocyanates; o-Toluidin …